All Photos(1)

Documents

Y0000666

Terazosin for system suitability

Name: Terazosin for system suitability
Brand: SIAL

CRS, European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Terazosin hydrochloride dihydrate, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride dihydrate

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₉H₂₅N₅O₄ · HCl · 2H₂O

CAS Number:

70024-40-7

Molecular Weight:

459.92

MDL number:

MFCD00941408

UNSPSC Code:

41116107

PubChem Substance ID:

329831082

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

terazosin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.O.Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

InChI key

NZMOFYDMGFQZLS-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

Looking for similar products? Visit Product Comparison Guide

General description

Terazosin hydrochloride is a quinazoline derivative. It is a alpha-1-selective adrenoceptor blocking agent. It has been used to treat hypertension, as it helps the blood vessels to relax, expand and improves blood flow.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

It may be used as drug standard stock solution for determination of terazosin hydrochloride dihydrate using potentiometric and fluorimetric techniques.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

Y0000622

Terazosin impurity A, European Pharmacopoeia (EP) Reference Standard

1643463

1643474

1643485

PHR3137

Pictograms

GHS07

Signal Word

Warning

Hazard Statements

H319

Precautionary Statements

P264 - P280 - P305 + P351 + P338 - P337 + P313

Hazard Classifications

Eye Irrit. 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Potentiometric and fluorimetric methods for the determination of terazosin HCl in drug substance and dosage forms.

Ismail, Nahla S., and Taghreed A. Mohamed.

International Journal of Electrochemical Science, 9, 7394-7394 (2014)

Effect of global and regional sympathetic blockade on arterial pressure during water deprivation in conscious rats.

Britta J Veitenheimer et al.

American journal of physiology. Heart and circulatory physiology, 303(8), H1022-H1034 (2012-08-21)

Forty-eight hours of water deprivation (WD) in conscious rats results in a paradoxical increase in mean arterial pressure (MAP). Previous studies suggest this may be due to increased sympathetic nerve activity (SNA). However, this remains to be investigated in conscious

A novel three-layered tablet for extended release with various layer formulations and in vitro release profiles.

Jun Sang Park et al.

Drug development and industrial pharmacy, 37(6), 664-672 (2011-04-01)

A novel three-layered tablet consisting of a water-soluble mid-layer and two barrier layers with swellable polymers was investigated to develop a preferable once-a-day formulation containing terazosin HCl as a hydrophilic model drug. When the tablet was exposed to a release

Ventral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine.

Karen M Alsene et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(12), 2346-2356 (2010-08-06)

The psychotomimetic drug D-amphetamine (AMPH), disrupts prepulse inhibition (PPI) of the startle response, an operational measure of sensorimotor gating that is deficient in schizophrenia patients. Historically, this effect has been attributed to dopaminergic substrates; however, AMPH also increases norepinephrine (NE)

Risk factors for intraoperative floppy iris syndrome: a meta-analysis.

Irini P Chatziralli et al.

Ophthalmology, 118(4), 730-735 (2010-12-21)

To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery. Systematic review and meta-analysis of the literature. Seventeen eligible studies (17 588 eyes)

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service